Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ny developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 ... ) has announced the addition of the ... Opportunities, 2018" report to their offering. ... Lack of data protection and old ... PIN codes have driven the growth of ...
(Date:6/19/2013)... 19, 2013 Synthetic Biologics, Inc. (NYSE MKT: SYN), ... of serious infectious diseases, announced today that Jeffrey Riley ... OneMedForum New York Conference on Thursday, June 27, 2013 at ... . Mr. Riley is scheduled to present at 8:40 a.m. ... presentation can be accessed by logging onto the web at ...
(Date:6/19/2013)... BREA, Calif. , June 19, 2013  Continuing ... of myocardial infarction (MI), Beckman Coulter , Inc. ... clearance of its new Access AccuTnI+3 troponin I assay ... "Clinicians have depended on Beckman Coulter,s ... the new AccuTnI+3 assay has the proven performance to ...
(Date:6/19/2013)... Bayer CropScience will honor Illinois beekeeper Steve McNair ... Award. The award will be announced at Bayer’s ... an event where supporters of pollinator health celebrate the ... , The Bayer Bee Care Community Leadership Award recognizes ... bee colony to benefit their community. Applicants are judged ...
Breaking Biology Technology:Global Biometric Systems Market Forecast Report - Opportunities to 2018 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 3Synthetic Biologics to Present at OneMedForum New York 2013 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4
... , CINCINNATI, Sept. 18 LCA-Vision Inc. (Nasdaq: ... correction services under the Lasik Plus (R) brand, announces that ... a member of the company,s board of directors effective September ... ophthalmology industry. Management of daily operations will be the ...
... N.J., Sept. 17 Regado Biosciences, a privately held company ... announced today that the European Patent Office (EPO) has notified ... claims directed to oligonucleotide modulators of blood coagulation factor aptamers ... Company,s portfolio extends the scope and breadth of Regado,s intellectual ...
... , , , , ... The US Food and Drug Administration (FDA) has approved Valturna(R) ... two key points within the renin system, also known as the ... This is the first approval for Valturna, which is indicated for ...
Cached Biology Technology:LCA-Vision Announces CEO Resignation 2Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers 2Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers 3Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 2Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 3Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 4Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 5Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 6Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 7
(Date:6/19/2013)... DETROIT Insulin is the most potent physiological ... the storage and synthesis of lipids, protein and ... the circulatory system. It also plays a major ... where the glucose is metabolized and removed from ... understanding the precise molecular mechanisms by which insulin ...
(Date:6/19/2013)... 2013  New York College of Health Professions announces ... and Trademark Office for detecting biometric changes through smart ... have been injured, attacked or killed. This ... Intellectual Properties Agreements of New York College of Health ... New York College says, "Our ...
(Date:6/19/2013)... European Medicines Agency (EMA) approved the modified adeno-associated ... therapy for clinical use in the Western world. ... S447X for the treatment of a rare inherited ... affects approximately one or two out of one ... of the pancreas. Afflicted individuals carry a defect ...
Breaking Biology News(10 mins):Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4No danger of cancer through gene therapy virus 2
... Common colds typically cause a week of sneezing, aches and ... and a few used sick days behind. But what if ... adenovirus type-3 is known as the "uncommon cold" because the ... to those of the common cold which is caused by ...
... of Census of Marine Life explorations as scientists uncover ... the global ocean. A world of marine discoveries including ... star, and Antarctica,s biggest-ever amphipod and other interesting, rare, ... http://earth.google.com/ocean . Or one can follow along on scientific ...
... been born 200 years ago come Feb. 12, but his ... And while the Origin of Species author might not have ... that the environment is changing. He would, however, be astonished ... "Every species is under temporary permanence," says Bill Saidel, ...
Cached Biology News:New vaccine developed for preventing 'uncommon cold' virus 2Evolution and climate change research advances at Rutgers-Camden 2
... the smallest thermal cyclers on the market, which ... 0.5ml (20 samples) or 0.2ml microtube (25 samples) ... and cooling rate of 3.6C/sec and 2.0C/sec respectively ... Fast track programming with new quick dial facility ...
... HRP Conjugate Stabilizer is an aqueous solution ... other non-toxic stabilizing chemicals in a MOPS ... 6.7. This product contains a combination ... ppm Proclin 300 (Rohm and Haas Company) ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: